Learn More
PURPOSE This phase III international study compared the efficacy and safety of a combination of pegylated liposomal doxorubicin (PLD) plus bortezomib with bortezomib monotherapy in patients with(More)
PURPOSE To determine whether the combination of pegylated liposomal doxorubicin (PLD) and docetaxel significantly prolongs time to disease progression compared with docetaxel alone without an(More)
e20522 Background: A randomized, multicenter phase 3 trial of PLD+D showed a significant improvement in the primary endpoint of time to progression (TTP) compared with D alone but with increased(More)
4029 Background: We conducted a trial for patients (pts) with loco-regional esophageal carcinoma consisting of pre-operative chemoradiation followed by surgery and then adjuvant chemotherapy. (More)
  • 1